Sponsored · Video

PharmAbcine Makes Great Strides in Immune-Oncology Cancer Treatments with Successful Trials

PharmAbcine’s CEO, Dr. Jin-San Yoo, speaks at BIO-Europe 2019 in Hamburg about the South Korean clinical stage immune-oncology company’s several successful and upcoming clinical trials in Melbourne, Australia, and elsewhere. PharmAbcine is a bioventure company specializing in R&D of antibody treatments through its new-generation double target antibody production technology using its potent non-immune scFv phage display library. They are continually developing pipelines for sustainable growth with a vision to release a new global blockbuster bio drug by 2020. They just opened a new US subsidiary in South San Francisco, and another in Brisbane, Australia.

Trending on Xconomy